*EMBARGOED All research presented at the 2020 ACG Annual Scientific Meeting and Postgraduate Course is strictly embargoed until Monday, October 26, 2020, at 8:00 am EDT.
P1478 Decreasing Prevalence of Colectomy for Ulcerative Colitis Coincides With Increased Utilization of Biologic Medications: A Temporal Analysis From 2000-2019
Author Insight from George Khoudari, MD, Cleveland Clinic Foundation
What’s new here and important for clinicians?
Recent reports suggest that early use of biologics may decrease colectomy rates in patients with ulcerative colitis. Therefore, using a large commercial database we performed a temporal trend analysis to compare the trend of UC prevalence and biologics utilization over 2 decades. We observed declining colectomy prevalence over the past 20 years going along with the increasing utilization of biologics.
What do patients need to know?
The treatment for ulcerative colitis disease has changed significantly over the past 20 years with biologics being initiated early. We observed a falling trend of colectomy prevalence that coincides with rising trend of biologics utilization. This finding is consistent with previous smaller studies and may suggest that biologic therapy maybe playing a role in the decreasing prevalence of colectomy over the years.
George Khoudari, MD, Cleveland Clinic Foundation
gkhoudary [at] gmail [dot] com
Media Interview Requests
To arrange an interview with any ACG experts or abstract authors, please contact Becky Abel of ACG via email at mediaonly [at] gi [dot] org or by phone at 301-263-9000.